Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NYSE:GLS

Gelesis (GLS) Stock Price, News & Analysis

Gelesis logo

About Gelesis Stock (NYSE:GLS)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.11
$0.33
52-Week Range
N/A
Volume
185,100 shs
Average Volume
386,034 shs
Market Capitalization
$11.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.

Receive GLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gelesis and its competitors with MarketBeat's FREE daily newsletter.

GLS Stock News Headlines

Gelesis Holdings Inc GLSHQ
This picture could hold the secret to the market's next move.
A strange investment secret — discovered just a few short weeks before this image was taken — correctly predicted it all. Even crazier, this secret accurately called every major financial event in recent history … Now it's signaling something very scary is about to hit the market again …
GLS Gelesis Holdings, Inc.
See More Headlines

GLS Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Gelesis investors own include VIQ Solutions (VQS), Faraday Future Intelligent Electric (FFIE), Eos Energy Enterprises (EOSE), Danimer Scientific (DNMR), Crown ElectroKinetics (CRKN), Boxed (BOXD) and BitNile Metaverse (BNMV).

Company Calendar

Today
5/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NYSE:GLS
Phone
N/A
Fax
N/A
Employees
2
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-56,030,000.00
Net Margins
-221.38%
Pretax Margin
-214.62%

Debt

Sales & Book Value

Annual Sales
$25.77 million
Price / Cash Flow
N/A
Book Value
($0.34) per share
Price / Book
N/A

Miscellaneous

Free Float
64,606,000
Market Cap
$11.63 million
Optionable
Not Optionable
Beta
0.88
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NYSE:GLS) was last updated on 5/12/2025 by MarketBeat.com Staff
From Our Partners